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Dietary supplementation with ω-3 polyunsaturated fatty acids (ω-3 PUFAs), speciﬁcally the
fatty acids docosahexaenoic acid (DHA; 22:6 ω-3) and eicosapentaenoic acid (EPA; 20:5
ω-3), is known to have beneﬁcial health effects including improvements in glucose and
lipid homeostasis and modulation of inﬂammation. To evaluate the efﬁcacy of two differ-
ent sources of ω-3 PUFAs, we performed gene expression proﬁling in the liver of mice
fed diets supplemented with either ﬁsh oil (FO) or krill oil (KO). We found that ω-3 PUFA
supplements derived from a phospholipid krill fraction (KO) downregulated the activity of
pathways involved in hepatic glucose production as well as lipid and cholesterol synthesis.
The data also suggested that KO-supplementation increases the activity of the mitochon-
drial respiratory chain. Surprisingly, an equimolar dose of EPA and DHA derived from FO
modulated fewer pathways than a KO-supplemented diet and did not modulate key meta-
bolic pathways regulated by KO, including glucose metabolism, lipid metabolism and the
mitochondrial respiratory chain. Moreover, FO upregulated the cholesterol synthesis path-
way, which was the opposite effect of krill-supplementation. Neither diet elicited changes
in plasma levels of lipids, glucose, or insulin, probably because the mice used in this study
were young and were fed a low-fat diet. Further studies of KO-supplementation using ani-
mal models of metabolic disorders and/or diets with a higher level of fat may be required
to observe these effects.
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INTRODUCTION
The liver plays a major role in controlling whole body carbohy-
drate and lipid metabolism by using dietary ω-6 and ω-3 fatty
acids and their respective products as sensors for nutritional
state. These fatty acids have the ability to target speciﬁc tran-
scription factors, e.g., peroxisome proliferator-activated receptor
α(PPARα),sterolregulatorelementbindingprotein-1c(SREBF1)
andtheheterodimerfromMLXinteractingprotein-like(MLXIPL
or ChREBP) and Max-like protein X (MLX; Jump et al., 2008a).
Consequently, fatty acids have the ability to control transcrip-
tion factor activity, which in turn regulates gene expression and
metabolic processes such as glycolysis, lipid biosynthesis, fatty
acid elongation, desaturation, and oxidation. Furthermore, ω-3
fatty acids have the ability to inﬂuence the abundance and activ-
ity of nuclear receptors by affecting their proteolytic processing
and phosphorylation states (Jump, 2004; Dentin et al., 2005a; Xu
et al., 2006). However, these speciﬁc regulatory effects are not
shared by all fatty acids. Two ω-3 polyunsaturated fatty acids
(ω-3 PUFAs) that can regulate gene expression, and are linked
to many beneﬁcial effects in human health and disease, are eicos-
apentaenoicacid(EPA)anddocosahexaenoicacid(DHA;Riediger
et al.,2009). These long-chain fatty acids are enriched in krill and
ﬁsh, though the EPA and DHA found in krill oil (KO) and ﬁsh
oil (FO) differ in their structural form: EPA and DHA in FO are
in the form of triglycerides, whereas KO contains the majority of
the EPA and DHA esteriﬁed into phospholipids (Winther et al.,
2011). In addition to a high level of phospholipids, KO contains
the antioxidant astaxanthin that protects the unsaturated bonds
from oxidative damage (Tou et al., 2007). The different struc-
tural fractions of fatty acids might affect incorporation into cells,
susceptibility to peroxidation, and bioavailability resulting in dif-
ferent molecular effects or different tissue speciﬁcities (Wijendran
et al., 2002; Batetta et al., 2009; Maki et al., 2009; Graf et al., 2010;
Ulven et al., 2011).
Despite the known differences in fatty acid and micronutrient
compositionsinFOandKOs,itisunknownif therearedifferential
effects of the two compounds in vivo. Therefore, we performed a
study to determine if consumption of a diet supplemented with
either FO or KO altered gene expression proﬁles of liver tissue
of mice fed diets varying in their lipid source (i.e., FO and KO)
but containing equal levels of of EPA and DHA. Our analysis
revealed that ω-3 PUFAs of different origin have mostly non-
overlappingeffectsatthegeneexpressionlevel,suchthatmarkedly
fewer genes and metabolic pathways were regulated by a FO (vs.
KO) supplemented diet.
MATERIALS AND METHODS
ANIMALS AND DIETS
Male CBA/J mice were purchased from Jackson Laboratory at
6weeks of age and were individually housed and fed 84kcal/week
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of a diet based on the AIN93M formulation (Reeves,1997). Start-
ing at 2months of age, mice were maintained on the Control diet
(containing 4% lipid from soybean oil) or were fed one of the
following two test diets (n =10 mice per group): supplemented
with FO (FO: 18/12 cholesterol-reduced FO, GC Rieber Oil AS,
Kristiansund,Norway),or supplemented with Superba™ KO (KO,
AkerBioMarineASA,Norway).Bothtestdietswerebasedonmod-
iﬁcations of the Control diet and were formulated by substituting
an equivalent amount of the soybean oil with either 1.1% FO or
1.5% KO. Fish and krill oil diets did not differ considerably in the
total amount of ω-3 PUFAs as the content of EPA and DHA in the
diets were 0.31% (FO) and 0.29% (KO). Fatty acid composition
of the diets are shown in Table 1. All diets were formulated by
Bio-Serv (Frenchtown, NJ, USA).
Body weight was measured once every 2weeks. At 5months of
age,micewereeuthanizedbycervicaldislocationafteranovernight
fast, blood was collected from the body cavity, and tissues were
rapidly dissected, ﬂash frozen in liquid nitrogen, and stored at
−80˚C.AllexperimentalprotocolsreceivedapprovalfromtheAni-
malCareandUseCommitteeattheWilliamS.MiddletonMemor-
ialVeteransHospital(Madison,WI,USA),whichisfullycompliant
with the American Physiological Society’s “Guiding Principles in
the Care and Use of Animals” (American Physiological Society,
2002).
MICROARRAY ANALYSIS
Gene expression proﬁling was performed as described previously
(Bargeretal.,2008).Brieﬂy,totalRNAwasextractedfromlivertis-
sue of seven mice per group and was processed according to stan-
dard protocols described by Affymetrix. Samples were hybridized
on the Affymetrix Mouse Genome 430 2.0 array which represents
>20,000knowngenes.Todeterminetheeffectof atestdietonthe
expression of a gene, the average signal intensity for the treated
group was compared to the average signal intensity for that gene
in the control group. Comparisons between groups were made
Table 1 | Fatty acid composition (grams per 100g of diet) of the three
diets as determined from reference values for the different lipid
sources.
Fatty acid Control FO KO
C14:0 0 0.08 0.06
C16:0 0.42 0.47 0.47
C18:0 0.18 0.16 0.12
C16:1 n-7 0 0.08 0.05
C18:1 n-9 0.90 0.81 0.74
C18:2 n-6 2.02 1.47 1.28
C18:3 n-3 0.27 0.20 0.18
C20:5 n-3 0 0.17 0.19
C22:6 n-3 0 0.11 0.11
SFA 0.63 0.73 0.68
MUFA 0.91 0.92 0.81
PUFA 2.31 2.08 1.81
n-3 0.27 0.54 0.50
n-6 2.02 1.49 1.29
n-3/n-6 ratio 0.13 0.36 0.39
using two-tailed t-tests (experimental vs. Control); a gene was
considered to be signiﬁcantly changed by treatment at p<0.01.
To identify functional classes of genes changed by treatment,
weperformedparametricanalysisof genesetenrichment(PAGE).
Thistechniqueallowsforanunbiasedandhighlysensitivemethod
of detecting classes of genes that are modulated by treatment
(Kim and Volsky, 2005). In addition, PAGE generates a z-score
indicating if a gene class was activated (z-score>0) or repressed
(z-score<0) by treatment. We grouped genes into functional
classes using the Reactome hierarchy (http://www.reactome.org;
Vastrik et al., 2007) and only considered Reactome terms that
were annotated with at least 10 but not more than 1000 genes
per term. Gene functional classes were considered to be sig-
niﬁcantly altered by treatment at p<0.001. Raw microarray
data have been archived at NCBI-GEO at can be accessed at
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE29572.
PLASMA ANALYSIS
Lipids and glucose were measured enzymatically on a Hitachi 917
system (Roche Diagnostics GmbH, Mannheim, Germany) using
the triglyceride (GPO–PAP) and cholesterol (CHOD–PAP) kits
from Roche Diagnostics (Mannheim, Germany) and the phos-
pholipid kit from DiaSys Diagnostic Systems GmbH (Holzheim,
Germany). Plasma insulin was measured using an ELISA kit from
Millipore (Billerica, MA, USA).
RESULTS
EFFECTS ON METABOLIC PATHWAYS ARE MORE PRONOUNCED WITH
KRILL OIL THAN FISH OIL ADMINISTRATION
Individually housed male, 2-month-old CBA/J mice were fed one
of three low-fat diets that were isocaloric, but differed in their
source of lipids: a control diet containing soybean oil (Control),
or a control diet either supplemented with FO or KO and bal-
anced for EPA and DHA concentration. Biweekly bodyweight did
not differ among the groups at any time point (data not shown).
At 5months of age the mice were euthanized and tissues were col-
lected for gene expression analysis by microarray and plasma was
collected for lipid measurements.
To determine if different sources of ω-3 PUFAs have differ-
ential effects at the molecular level, we performed gene expres-
sion proﬁling in liver and compared the effect of FO and KO
diets to the Control diet. Of the 20,118 genes represented on the
array, 192 genes were signiﬁcantly changed in expression by FO,
whereas 4,892 genes were signiﬁcantly changed in expression by
KO (p<0.01 treated vs. control). Of the 51 genes that were sig-
niﬁcantly changed by both diets, 44/51 genes were changed in the
same direction. Similarly, pathway analysis using PAGE revealed
a more robust effect of KO vs FO. Speciﬁcally, 52 pathways were
signiﬁcantly modulated by KO, whereas only four pathways were
inﬂuenced by FO in the diet (p<0.001; Figure 1). All four path-
ways modulated by FO were also modulated by KO; however, one
pathway (“Cholesterol biosynthesis”) was differentially regulated
between the two diets such that FO increased the activity of this
pathway,whereasKOdecreasedtheactivity.Becausethetwoexper-
imentaldietscontainedidenticalconcentrationsof EPAandDHA
(0.3%),these data clearly show that KO is more bioactive than FO
on gene expression in the liver.
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FIGURE 1 | Metabolic pathways regulated by either ﬁsh oil (FO) or krill
oil (KO) in mouse liver. Pathway analysis (PAGE, see Materials and
Methods) was used to identify functional classes of genes from the
Reactome database that were differentially regulated in supplemented
diets compared to the Control diet at p<0.001. Red or blue ﬁlls represent
the magnitude of the z-score and indicate if a pathway was signiﬁcantly
increased or decreased in activity (respectively) by treatment. Each row
represents an individual Reactome pathway and each column represents
the effect of either FO or KO on that pathway. Only those Reactome IDs
represented by at least 10, but not more than 1000, genes are shown.
Pathways indicated by bold are discussed in detail in the manuscript.
GENES REGULATING HEPATIC GLUCOSE PRODUCTION ARE DECREASED
AFTER KO AND FO TREATMENT
Pathway analysis of the hepatic transcriptome revealed that there
wasadecreaseintheactivityof thepathway“Glucosemetabolism”
(Reactome ID 969399) for both the KO and FO diets compared to
controls (Figure2).Although only one gene in this pathway (Pklr,
pyruvatekinase,liverandredbloodcell)wassigniﬁcantlychanged
in expression by FO, PAGE revealed that the pathway overall was
modulated because there were modest, yet consistent effects of
FO on genes in this functional category (data not shown). The
ability of ω-3 PUFAs to decrease glucose metabolism, compared
to controls with the same energy intake, may be regulated at the
FIGURE 2 | Gene expression heatmap for genes involved in glucose
metabolism. PAGE analysis showed a statistically signiﬁcant effect of ﬁsh
oil (FO) and krill oil (KO) on the Reactome pathway “Glucose metabolism.”
All genes annotated in this pathway and changed in expression by at least
one treatment are shown.Two-tailed t-tests were used to determine
signiﬁcant changes at p<0.01 between treatment and the Control group.
early stages of glycolysis by decreasing glucose uptake through
downregulation of the liver-speciﬁc glucose transporter (Slc2a2).
Indeed, KO showed a trend for 25% decreased Slc2a2 expression
(−1.3-fold change; p=0.037).
Parametric analysis of gene set enrichment also revealed a
signiﬁcantdownregulation(p<0.001)inthepathway“Gluconeo-
genesis”(ReactomeID969398)onlyintheKOgroup(Figure3A).
In addition, several genes known to regulate hepatic glucose pro-
duction (but not yet annotated by the Reactome consortium)
were decreased in expression in the KO group, providing fur-
ther evidence for decreased hepatic gluconeogenesis. Two of these
genes,peroxisomeproliferator-activatedreceptor γ coactivator 1α
(Ppargc1a or Pgc-1α) and hepatocyte nuclear factor 4α (Hnf4a),
are master regulators of metabolic gene transcription and have
potent physiological effects on hepatic gluconeogenesis (Yoon
et al., 2001). Both Ppargc1a (Figure 3B) and Hnf4a (Figure 3C)
expression were signiﬁcantly decreased by the KO diet (−1.5-fold
change, p=0.01 and −3.6-fold change, p<0.001, respectively),
as was a downstream target of these transcriptional regulators,
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FIGURE 3 | Gene expression heatmap and transcriptional regulators of gluconeogenesis. Pathway analysis revealed a signiﬁcant downregulation of the
Reactome pathway “Gluconeogenesis” by KO (A). In addition, only KO signiﬁcantly decreased the expression of genes regulating hepatic gluconeogenesis,
including Ppargc1a (B), Hnf4a (C), and Pck1 (D).
phosphoenolpyruvate carboxykinase 1 (Pck1). The Pck1 gene
encodes an enzyme that exerts control over hepatic glucose pro-
duction, and Pck1 was signiﬁcantly decreased in expression only
by KO (−2.6-fold change, p=0.0002, Figure 3D). Despite the
decreased expression of genes involved in gluconeogenesis,we did
not observe signiﬁcant alterations in the levels of plasma glucose
in either the FO or KO groups compared to the Control group
(Table 2).
DIFFERENT EFFECTS OF KO AND FO DIETS ON HEPATIC LIPID
METABOLISM
Geneexpressionproﬁlingandpathwayanalysisalsosuggestedthat
FO and KO differ in their ability to regulate hepatic lipid metab-
olism. Speciﬁcally, KO signiﬁcantly downregulated the activity
of the pathway “Metabolism of lipids and lipoproteins” (Reac-
tome ID 969435), whereas FO had no effect on this pathway
(Figure 4A). Two key regulators of the hepatic lipid metabolism
are the transcription cofactors SREBF1 and MLXIPL. Both were
signiﬁcantly decreased in expression in the KO group (−2.4-fold
change, p=0.002 for Srebf1 and −5.8-fold change, p<0.001 for
Mlxipl), whereas FO had no effect on the expression of these
genes (Figures 4B,C). In addition to the decreased expression
of these transcriptional cofactors, three downstream targets of
Table 2 | Effect of FO and KO on selected plasma measurements.
Control FO KO
Triacylglycerol (mmol/L) 1.55±0.17 1.72±0.65 1.91±0.32
Total cholesterol (mmol/L) 3.59±0.30 3.32±0.39 3.75±0.37
Free fatty acids (mmol/L) 0.79±0.07 0.88±0.17 0.65±0.20
Phospholipids (mmol/L) 3.24±0.33 3.03±0.37 3.24±0.26
Glucose (mmol/L) 8.68±1.91 7 .50±1.35 8.13±1.04
Insulin (ng/mL) 0.59±0.09 0.78±0.17 0.71±0.26
All values represent mean±S.D. (n=5–8). No signiﬁcant changes could be
detected by one-way ANOVA.
these regulatory genes (Dentin et al., 2005b) were signiﬁcantly
decreased after supplementing KO to the diet (p<0.001): ATP
citrate lyase (Acly) catalyzes the conversion of citrate to acetyl
CoA for synthesis of fatty acids and showed a −2.0-fold change
with KO (Figure 4A); fatty acid synthase (Fasn, Figure 4A) and
acetyl CoA carboxylase alpha (Acaca, Figure 4D), catalyze two of
the initial steps of fatty acid synthesis and both were decreased
with KO supplementation (−3.3-fold and −2.7-fold change,
respectively).
Krill oil,but not FO,supplementation also was associated with
a signiﬁcant downregulation of the pathway “Fatty acid, triacyl-
glycerol and ketone body metabolism” (Reactome ID 969434;
Figure 4E). Signiﬁcant decreases in the expression of key genes
involved in mitochondrial β-oxidation were observed only in the
KO group, including the transcription factor PPARα (−5.1-fold
change) and the liver isoform of the rate-limiting enzymes carni-
tine palmitoyltransferase 1a and 2 (Cpt1a, −2.4-fold change and
Cpt2,−1.6-fold change; Figure4D). Moreover,four genes encod-
ing enzymes involved in mitochondrial fatty acid β-oxidation
(Acads,Acadm,Acadl,and Acadvl) were all signiﬁcantly decreased
in expression in the KO group (−1.4 to −1.8-fold change, see
Figure 4D). FO however, did not affect the expression of any of
the above genes.
Parametric analysis of gene set enrichment analysis further
revealed that FO signiﬁcantly upregulated the Reactome path-
way “Cholesterol biosynthesis” (Reactome ID 969930), while a
KO diet downregulated this pathway (Figure 4F). Speciﬁcally,
KO resulted in a signiﬁcant decrease in the expression of two
key genes in the pathway of cholesterol metabolism: 3-hydroxy-
3-methylglutaryl-coenzyme A reductase (Hmgcr, the gene encod-
ing the rate-limiting enzyme for cholesterol synthesis, −1.9-fold
change) and phosphomevalonate kinase (Pmvk, the gene encod-
ing the protein that catalyzes the ﬁfth condensation reaction in
cholesterol synthesis, −2.0-fold change; see Figure 4F). Other
studies suggest that the hyperlipidemic effects of dietary satu-
ratedfatsaremediatedthroughincreasedactivityof Ppargc1b and
Srebf2 (Lin et al., 2005; Lelliott et al., 2007), and we observed a
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FIGURE 4 | Diverse effects of krill oil on genes regulating lipid
metabolism in mouse liver. Pathway analysis revealed a signiﬁcant
downregulation by KO on the Reactome pathway “Metabolism of lipids and
lipoproteins” (A) as well as three key transcriptional regulators of lipid
metabolism, including Srebf1 (B), Mlxipl (C), and Acaca (D). Individual gene
symbols could not be represented for all genes in this pathway; two genes
described in the Results section are highlighted with their respective gene
symbols. In addition, KO downregulated the activity of the Reactome pathway
“Fatty acid, triacylglycerol and ketone body metabolism” (E); genes
highlighted in the Results section are indicated with an asterisk. Pathway
analysis also revealed that FO upregulated, whereas KO downregulated, the
Reactome pathway “Cholesterol metabolism” (F).Two regulatory genes in
cholesterol synthesis are highlighted in the Results and indicated with an
asterisk.Two transcriptional cofactors that are upstream regulators of
cholesterol synthesis [Ppargc1b, (G) and Srebf2, (H)] were also decreased in
expression only by KO.
signiﬁcant (p<0.001) downregulation of these genes in the KO
group (−7.9-fold change for Ppargc1b, Figure 4G and −3.2-fold
change for Srebf2, Figure 4H). Thus, these data support previous
studiesdemonstratingthattheliverissensitivetothesaturationof
dietary fatty acids,and that PPARGC1B and SREBF2 activity may
be the important regulators of cholesterol synthesis in response to
dietary fatty acid saturation.
Plasma analysis showed no signiﬁcant changes in triglyceride,
total cholesterol, free fatty acids, phospholipids, or insulin levels
in either treatment groups (Table 2).
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INCREASED MITOCHONDRIAL RESPIRATORY ACTIVITY AND
IMPLICATIONS FOR REDUCED ENDOGENOUS OXIDATIVE DAMAGE IN
THE KO GROUP
Parametricanalysisofgenesetenrichmentrevealedthatonlyfeed-
ing of a KO and not FO diet to mice resulted in a signiﬁcant
activation of the Reactome pathway “Respiratory electron trans-
port”(ID 969800,Figure5A). This response was largely driven by
an increased expression of genes encoding subunits of Complex I
(NADH dehydrogenase). Noteworthy is also the increased expres-
sion of sirtuin 3 (Sirt3) only in the KO treated animals (1.7-fold
change, Figure 5B). Sirt3 is a regulator of mitochondrial energy
metabolism,particularly Complex I (Ahn et al., 2008).
DISCUSSION
Gene expression proﬁling and pathway analysis demonstrated
that krill-supplementation regulates genes with diverse aspects of
hepatic energy metabolism, including glucose metabolism, lipid
biosynthesis, fatty acid metabolism, and cholesterol biosynthesis.
Importantly, these transcriptional effects are in strong agreement
with published reports showing beneﬁcial effects of krill-
supplementation on circulating levels of glucose and cholesterol
(Batetta et al., 2009; Tandy et al., 2009). Although we did not
observe changes in plasma glucose or lipids in this study, this is
likely because our study involved young, healthy mice fed a low-
fat diet. For example, two recent studies demonstrate that KO
FIGURE 5 | Upregulation of mitochondrial energy metabolism in liver
of mice consuming KO. Pathway analysis revealed a signiﬁcant
upregulation of the pathway “Respiratory electron transport” in the KO
group (A). A transcriptional regulator of nuclear genes regulating
mitochondrial energy metabolism, Sirt3, was also upregulated by KO (B).
supplementation improves parameters of hepatic lipid metabo-
lismingeneticanddiet-inducedanimalmodelsof obesity(Batetta
etal.,2009;Tandyetal.,2009).Becausehepaticlipidaccumulation
(steatosis) is associated with insulin resistance and the metabolic
syndrome in humans (Parekh and Anania, 2007), the transcrip-
tomic ﬁndings from this study provide evidence that KO may
havebeneﬁcialeffectsonhepaticlipidmetabolismassociatedwith
metabolic disease in humans (Bunea et al.,2004).
Elevated hepatic glucose production is associated with meta-
bolic disease in humans (Natali and Ferrannini, 2006) and we
observed that KO supplementation favorably altered the expres-
sionof genesregulatinghepaticglucosemetabolism.Forexample,
the expression of Ppargc1a and Hnf4a is increased in the liver of
humans with type 2 diabetes and in mouse models of diabetes
(Herzig et al., 2001; Puigserver, 2005; Liang et al., 2009), and we
observed that expression of these genes was decreased after KO
treatment (Figures 3A,B). Suppression of gluconeogenesis and
hepatic glucose output via modulation of PGC-1α activity has
been proposed as a therapeutic target for the treatment of type 2
diabetes,providedthattheinterventiondoesnotopposethebene-
ﬁcialeffectsof Ppargc1a expressioninothertissues.Onestudyhas
shownthatKOlowerscirculatingglucoseinhumans(Buneaetal.,
2004),suggestingthatthekrillsupplementsusedinthisstudymay
functionallydecreasehepaticglucoseproductionandincreaseglu-
cose uptake in tissues other than liver. Transcriptomic analysis in
other tissues of krill-treated mice would reveal if PGC-1α activ-
ity on regulation of metabolic genes is seen in other peripheral
tissues.
Interestingly,FO had rather modest effects on metabolic path-
ways regulated by the KO-supplemented diet (Figure 1). For
example the pathway“Fatty acid, triacylglycerol and ketone body
metabolism” was not modulated by a FO-supplemented diet
(Figure 4E). The reason for the discrepancy between the effect
of FO in this study and previous reports (Price et al.,2000;Clarke,
2004; Jump, 2008b) showing that ω-3 PUFAs increase fatty acid
oxidation is not clear, but might be related to the relatively low
dose of EPA and DHA used in the current study. In our study,
the content of EPA and DHA was approximately 0.3%, whereas
FO-supplemented diets usually contain much higher doses, with
concentrations around 5% (Mori et al., 2007; Wergedahl et al.,
2009; Tsuduki et al., 2011). Nonetheless, we observed marked
transcriptional effects of KO at a low dose, suggesting that krill-
derived ω-3 PUFAs are bioactive, when present in the diet at a
low concentration. One characteristic of KO is the predominant
presence of EPA and DHA in the phospholipid form. The amount
of phospholipids in KO is around 40–45%. It is a complex mix-
ture of 69 different choline-containing phospholipid molecules
(LeGrandoisetal.,2009;Wintheretal.,2011).Themajorityofω-3
fatty acids are EPA and DHA,but also stearidonic acid and docos-
apentaenoic acid are present in smaller quantities. FO contains
ω-3 fatty acids in triglyceride form. This might explain the differ-
ent bioavailabilities and tissue distributions observed for EPA and
DHA in phospholipid versus triglyceride form (Wijendran et al.,
2002; Maki et al., 2009; Graf et al., 2010; Ulven et al., 2011). The
exactmechanismsbehindarenotknown,butithasbeenproposed
thatthedifferentmolecularformscoulddetermineinwhichblood
pool the fatty acids end up, which might inﬂuence tissue distrib-
ution (Amate et al., 2001). Different hepatic levels of ω-3 PUFAs
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might in turn explain the observed differential gene expression
proﬁles between the KO and FO groups.
InadditiontoshowingthatKOaffectsmultiplemetabolicpath-
ways, our data also suggests a molecular mechanism by which
krill-derivedω-3PUFAsaltertheexpressionof keytranscriptional
cofactorsthathavedownstreameffectsonexpressionof metabolic
genes. For example, expression and activity of the genes encod-
ing the transcriptional cofactors Srebf1 and Mlxipl are increased
by insulin, resulting in a stimulation of glycolysis and hepatic
lipogenesis leading to lipid accumulation and insulin resistance
in the liver (Dentin et al., 2005b; Iizuka and Horikawa, 2008).
Conversely, inhibition or deﬁciency of these proteins ameliorates
metabolic abnormalities in mouse models of the metabolic syn-
drome(Iizukaetal.,2004;Dentinetal.,2006a).WefoundthatKO
robustly decreased the expression of these genes (Figures 4B,C)
which is in agreement with other studies showing that ω-3 PUFAs
decrease the activity of these proteins (Xu et al.,2002;Sekiya et al.,
2003;Dentinetal.,2006b).TheobservationthatKOreducedFasn
andAcaca alsosupportstheﬁndinginastudyinrat,whichshowed
that KO signiﬁcantly reduced the activity of three key enzymes in
lipogenesis in liver (Ferramosca et al.,2011).
The current study also provides evidence that krill-
supplementation may stimulate mitochondrial respiratory activ-
ity, a pathway which is repressed in humans with type 2 diabetes
(Mootha et al., 2003). We found a coordinated upregulation of
nuclear-encoded genes regulating mitochondrial electron trans-
port (Figure 5A), and this agrees with a large number of studies
showing that increases in the PUFA content of the diet are asso-
ciated with changes in metabolic rate (Hulbert et al., 2005). In
addition to an increase of genes coding for subunits of complex I
of the electron transport chain,a change in the expression of Sirt3
was observed with KO treatment. Sirtuins are a family of genes
associated with metabolic control, and in humans elevated Sirt3
expression is associated with increased lifespan (Rose et al., 2003;
Bellizzi et al., 2005; Lanza et al., 2008). It is therefore interesting
to note that KO, but not FO signiﬁcantly upregulated Sirt3 in
this study. SIRT3 deacetylates several targets, including proteins
of complex I,which is important for maintaining basalATP levels
(Ahn et al., 2008). A KO-induced stimulation of ATP production
could be of interest in combating aging-associated decline of ATP
levels.
CONCLUSION
Our data demonstrate a marked effect of KO on the regulation
of genes and pathways involved in hepatic energy metabolism.
Speciﬁcally, the effects of KO were the opposite of the metabolic
dysregulation seen in obesity and type 2 diabetes. Dietary supple-
mentation with KO elicited a transcriptional proﬁle that suggests
improvedglucose,lipid,andcholesterolmetabolismandincreased
mitochondrial respiration. Furthermore, our data also suggest
a mechanism whereby krill-derived ω-3 PUFAs may inﬂuence
metabolism through upstream transcriptional activation of PGC-
1α,PGC-1β,SREBF1,and MLXIPL. The differential expression of
key transcriptional regulators likely has multiplicative effects on
the expression of downstream genes, and this may explain why a
large number of genes were changed in expression in response to
KO. Surprisingly, these effects were not observed in mice receiv-
ing a diet supplemented with FO containing an equivalent level of
PUFAs,emphasizing the inﬂuence that the structural form of ω-3
PUFAs (esteriﬁed to either phospholipids or triglycerides) has on
exerting a biological response. Overall, the data provide support
for a role of KO in ameliorating abnormalities seen with obesity
and insulin resistance; further studies in other animal models will
be needed to conﬁrm if the gene expression patterns observed in
this study have effects on metabolic disease.
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